Descriptions of Benefits and Risks in Consent Forms for Phase 1 Oncology Trials
Authors:
- Ezekiel J. EmanuelEEEzekiel J. Emanuel
- Benjamin WilfondBWBenjamin Wilfond
- Jonathan RackoffJRJonathan Rackoff
- Karen MartzKMKaren Martz
- Christine GradyCGChristine Grady
Open Access
- 26 December 2002
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 347 (26) , 2134-2140
Abstract
Ethicists have suggested that written consent forms encourage participants in phase 1 cancer trials to expect benefit from the experimental agent and to overlook serious risks.Keywords
This publication has 20 references indexed in Scilit:
- Informed consent and decision-making: patients’ experiences of the process of recruitment to phases I and II anti-cancer drug trialsPatient Education and Counseling, 2002
- Quality of informed consent in cancer clinical trials: a cross-sectional surveyThe Lancet, 2001
- Phase I Cancer Trials: A Crucible of Competing PrioritiesInternational Anesthesiology Clinics, 2001
- Quantitative Analysis of Ethical Issues in Phase I Trials: A Survey Interview Study of 144 Advanced Cancer PatientsIRB: Ethics & Human Research, 2000
- Defining and Describing Benefit Appropriately in Clinical TrialsJournal of Law, Medicine & Ethics, 2000
- Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in JapanCancer Chemotherapy and Pharmacology, 1994
- Response rates, duration of response, and dose response effects in phase I studies of antineoplasticsInvestigational New Drugs, 1991
- Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer.BMJ, 1986
- On the nature and ethics of phase I clinical trials of cancer chemotherapies1982
- How readable are subject consent forms?1980